Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Methanol

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Methanol. Displaying page 1 of 1.
    EudraCT Number: 2020-000829-55 Sponsor Protocol Number: PSILO4ALCO Start Date*: 2020-12-16
    Sponsor Name:Psychiatric Centre Copenhagen
    Full Title: Can a one-off administration of psilocybin reduce alcohol intake in patients with alcohol use disorder? A randomized, double-blinded, placebo-controlled clinical trial.
    Medical condition: Alcohol Use Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10001594 Alcohol dependence syndrome LLT
    21.1 10037175 - Psychiatric disorders 10001590 Alcohol addiction LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006486-38 Sponsor Protocol Number: ComplexitDOC_PSI Start Date*: 2022-08-17
    Sponsor Name:University of Liege
    Full Title: Complexity-enhancing drugs to treat disorders of consciousness (DoC): a psilocybin study
    Medical condition: Disorders of consciousness as unresponsive wakefulness syndrome (UWS) and minimally conscious state (MCS) after a coma due to acquired brain injury.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002369-14 Sponsor Protocol Number: CHUB-Psy-PAThforsAUD Start Date*: 2023-07-20
    Sponsor Name:CHU Brugmann
    Full Title: Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)cognitive Mechanisms.
    Medical condition: Severe Alcohol Use Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.0 10037175 - Psychiatric disorders 10001584 Alcohol abuse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004767-77 Sponsor Protocol Number: IM018-005 Start Date*: 2021-10-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis
    Medical condition: Moderate to Severe Atopic Dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005565-13 Sponsor Protocol Number: 17000139BLC2002 Start Date*: 2021-10-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are...
    Medical condition: Muscle-Invasive Urothelial Carcinoma of the Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    21.0 100000004864 10046720 Urothelial carcinoma bladder stage II LLT
    21.0 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    21.0 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 04:58:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA